abrdn Healthcare Investors Business Summary

abrdn Healthcare Investors (HQH) is a non-diversified, closed-end management investment company that generates revenue primarily through asset-based management fees, currently set at 0.98% of managed assets. The fund’s business model centers on achieving long-term capital appreciation and providing regular income through a managed distribution policy, which targets quarterly payouts of approximately 2% of net asset value (NAV). Its primary business segments are concentrated in the healthcare sector, with a heavy emphasis on biotechnology, pharmaceuticals, medical devices, and healthcare services. HQH distinguishes itself by investing in both public and private entities, maintaining the flexibility to allocate up to 40% of its portfolio to restricted securities of emerging growth companies. Within the specialized healthcare closed-end fund (CEF) market, HQH competes directly with the BlackRock Health Sciences Trust (BME), BlackRock Health Sciences Trust II (BMEZ), and its sister fund, abrdn Life Sciences Investors (HQL). It occupies a niche as a high-yield vehicle for investors seeking exposure to late-stage clinical innovation and commercial-stage healthcare leaders, often trading at a persistent discount to NAV. Originally established in 1986 as Tekla Healthcare Investors, the fund’s leadership is currently spearheaded by a specialized investment team that transitioned to abrdn Inc. in late 2023. The executive team is led by Dr. Daniel R. Omstead, who serves as President and Portfolio Manager, bringing over two decades of experience from his tenure at Tekla Capital Management. He is supported by Dr. Jason C. Akus, Head of Healthcare Investments and Portfolio Manager, who holds both an M.D. and an MBA, and Dr. Frank T. Gentile, Senior Vice President of Research. The Board of Trustees is chaired by Todd Reit and includes independent members such as Jeffrey A. Bailey, Rose DiMartino, and C. William Maher, alongside Christian Pittard, abrdn’s Head of Closed-End Funds. Notable institutional backing includes significant positions held by the Royal Bank of Canada, Goldman Sachs, and Morgan Stanley, reflecting the fund's standing as a core institutional holding in the healthcare equity space.